29.00
Schlusskurs vom Vortag:
$29.04
Offen:
$28.94
24-Stunden-Volumen:
1.63M
Relative Volume:
0.71
Marktkapitalisierung:
$3.55B
Einnahmen:
$59.61M
Nettoeinkommen (Verlust:
$-262.14M
KGV:
-7.398
EPS:
-3.92
Netto-Cashflow:
$-247.49M
1W Leistung:
+0.10%
1M Leistung:
-1.46%
6M Leistung:
+110.76%
1J Leistung:
+99.18%
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Firmenname
Arcutis Biotherapeutics Inc
Sektor
Branche
Telefon
805-418-5006
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Vergleichen Sie ARQT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics Inc
|
29.00 | 3.56B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Eingeleitet | Goldman | Neutral |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-10-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-09-07 | Eingeleitet | Needham | Buy |
| 2022-03-17 | Eingeleitet | Goldman | Buy |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Hochstufung | Goldman | Neutral → Buy |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-02-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Eingeleitet | Cowen | Outperform |
| 2020-02-25 | Eingeleitet | Goldman | Neutral |
| 2020-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates - ts2.tech
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day - ts2.tech
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 3.4%Still a Buy? - MarketBeat
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade - ts2.tech
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Rating Lowered by Zacks Research - MarketBeat
Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by Simplify Asset Management Inc. - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded by Wall Street Zen to Buy - MarketBeat
Arcutis Biotherapeutics Earnings Notes - Trefis
Is Suvretta’s Stake Cut and FDA’s Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - The Motley Fool
Why Arcutis Biotherapeutics Inc. stock remains resilientRate Cut & Weekly Watchlist of Top Performers - Улправда
Perpetual Ltd Increases Stake in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Will Arcutis Biotherapeutics Inc. stock gain from strong economyJuly 2025 Pullbacks & Technical Pattern Alert System - Улправда
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? - Yahoo Finance Australia
Is Arcutis Biotherapeutics Inc. stock attractive for growth ETFsJuly 2025 EndofMonth & Momentum Based Trading Ideas - DonanımHaber
Price Action: Why Arcutis Biotherapeutics Inc. stock remains resilientJuly 2025 Review & Low Risk Entry Point Tips - Улправда
Investor Mood: What Wall Street predicts for Arcutis Biotherapeutics Inc. stock priceJuly 2025 Selloffs & Weekly Setup with ROI Potential - Улправда
What Wall Street predicts for Arcutis Biotherapeutics Inc. stock priceJuly 2025 Spike Watch & Detailed Earnings Play Alerts - Улправда
Zacks Industry Outlook Arcutis, Amicus and ANI - The Globe and Mail
Will Arcutis Biotherapeutics Inc. stock beat EPS estimatesMarket Movers & Low Drawdown Investment Ideas - Улправда
Squarepoint Ops LLC Has $2.35 Million Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 11,500 Shares of Stock - MarketBeat
Looking Into Arcutis Biotherapeutics Inc's Recent Short Interest - Sahm
Arcutis Biotherapeutics Executive Sells Shares - TradingView — Track All Markets
Arcutis Biotherapeutics Insider Sold Shares Worth $332,851, According to a Recent SEC Filing - marketscreener.com
VP Burnett Sells 11,500 ($332.9K) Of Arcutis Biotherapeutics Inc [ARQT] - TradingView — Track All Markets
Arcutis (ARQT) CMO exercises options, sells 11,500 shares in plan trade - Stock Titan
This Biotech Stock Could Cure Your Portfolio's Pain - Finviz
Assessing Arcutis Biotherapeutics After 99% YTD Surge and Mixed Valuation Signals - Yahoo Finance
Arcutis Biotherapeutics, Inc. $ARQT Holdings Boosted by Frazier Life Sciences Management L.P. - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Gilder Gagnon Howe & Co. LLC Purchases 59,712 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Eczema awareness campaign launched by actress Tori Spelling and Dr. Adam Friedman - KOKH
ARQT (Arcutis Biotherapeutics) OCF Margin % : -1.77% (As of Sep. 2025) - GuruFocus
Tori Spelling Teams Up with Arcutis to Share Her Family’s Eczema Journey - WKEF
Norges Bank Takes $2.45 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now? - sharewise.com
Stempoint Capital LP Sells 334,401 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4.7%What's Next? - MarketBeat
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected - simplywall.st
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - BioSpace
Arcutis Biotherapeutics Appoints Amit Munshi as New Director - TipRanks
Amit Munshi joins Arcutis board as founder Chaudhuri retires - Investing.com
Arcutis Biotherapeutics Announces Board Changes - TradingView — Track All Markets
Amit Munshi joins Arcutis board as founder Chaudhuri retires By Investing.com - Investing.com India
Arcutis strengthens board of directors with new appointment of Amit Munshi - marketscreener.com
Arcutis Biotherapeutics | 12/8/25 - Channel 13 Las Vegas News KTNV
Arcutis Biotherapeutics: The Earnings Inflection Has Arrived (ARQT) - Seeking Alpha
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arcutis Biotherapeutics Inc-Aktie (ARQT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Burnett Patrick | See Remarks |
Dec 15 '25 |
Option Exercise |
3.64 |
11,500 |
41,860 |
109,807 |
| Burnett Patrick | See Remarks |
Dec 15 '25 |
Sale |
28.94 |
11,500 |
332,851 |
98,307 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):